◼ Archived
Business
Sanofi scraps STAT6 degrader from Nurix just 2 months after entering clinic
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Sanofi
8 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
Sanofi and Regeneron have deepened their immunology alliance in a deal worth up to $8 billion to secure early-stage assets and a Dupixent successor.
◼ Archived
Business
🔮 fades ✓
New drug shows promise in reducing COPD symptoms in former and current smokers, clinical trials show
AstraZeneca and Sanofi detail new respiratory clinical data at the #ERS26 conference.
◼ Archived
Business
🔮 holds ✗
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
Sanofi is scrapping plans for an eczema drug derived from its billion-dollar Kymab acquisition following a strategic pipeline review.
◼ Archived
Business
🔮 fades
Johns Hopkins surgeon highlights AI breakthrough that could spot pancreatic cancer before doctors
A Johns Hopkins surgeon reveals an AI breakthrough capable of detecting pancreatic cancer earlier than human physicians.
◼ Archived
Business
🔮 holds
Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector
Sanofi's Sarclisa becomes the first cancer drug to receive FDA approval for delivery via a wearable on-body injector for multiple myeloma patients.
◼ Archived
Business
🔮 fades
Sanofi under antitrust probe as European Commission kicks off formal proceedings
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.